Volume 10 Supplement 2
The observed incidence of anaphylaxis and serum sickness in patients receiving omalizumab in a tertiary allergy and asthma clinic in Canada
© MacRae et al; licensee BioMed Central Ltd. 2014
Published: 18 December 2014
In a post-marketing analysis last updated in July 2007, the FDA reported that an estimated 0.2% of patients suffered treatment related anaphylaxis and rare incidence of serum sickness. To substantiate this, the occurrence of treatment related anaphylaxis and serum sickness in our large Canadian allergy and asthma tertiary clinic was assessed.
A retrospective chart review of our database of omalizumab administration between 1998 and June 2014 was performed.
During clinical trials and with our post market experience, between 1998 and June 2014, over 21,000 injections of omalizumab to more than 250 patients were administered and no cases of anaphylaxis or serum sickness like symptoms were observed.
Meticulous care was taken by our omalizumab administration clinic to ensure optimal safety based on the emphasized warnings of anaphylaxis, as well as, the indicated warnings and precautions for serum sickness. Data collected in this analysis observed no cases of anaphylaxis or serum sickness like symptoms in the treatment of over 250 patients, during a period of 15.5 years, who combined received 21,000 injections of omalizumab thus confirming the low incidence of both anaphylaxis and serum sickness.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.